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THE USE OF RADIOACTIVE GOLD IN THE TREATMENT
OF CANCER OF THE CERVIX
ANDRE-W H . VELDHUIS, M.D.*,

L. A. SWINEHART, M.D.*,

L. E. PREUSS, M.S.**

The cure of metastatic malignancy by surgical extirpation, radiation therapy, or a
combination of the two has achieved only limited success. Few patients are saved by
operation when the lymph nodes contain cancer cells. Recurrences in irradiated patients
are frequent. The implication seems to be that viable tumor cells are present outside
the limits of surgical extirpation and beyond the bounds of effective irradiation. Better
results can only be achieved by more extensive surgery or by radiation. Radical surgery
is probably approaching its limit. Treatment with chemotherapeutic agents has thus
far been discouraging. New and improved methods of radiation seem to offer the
best chance of increasing survival figures.
In radiological therapeutics the cancericidal effect is produced by means of tissue
ionization. The limits of tolerance of normal tissue to externally applied gamma and
x-irradiation have been the chief therapeutic barrier. The development of supravoltage
x-ray machines and the substitution of Cobalt'" as a source of radiant energy have
resulted in a more uniform depth dose but have not increased the tolerance of normal
tissues to radiation. Unfortunately, during the procedure of radiation, normal tissues
cannot completely be dissected or positioned out of the path of the radiant energy.
The development of the pile as a source of energy characterized by the intense
neutron flux has resulted in the development of a number of beta emitting radioactive
isotopes. Therapeutically, radioactive colloidal gold is being used with increasing frequency. Its empirical record has been encouraging.
Radioactive gold possesses certain properties that make it an effective agent for
interstitial injection:
1. The colloidal particles are eagerly ingested by macrophages.
2. 95 percent of the tissue ionization produced originates with the beta radiation.
Radiation consists of three beta and three gamma rays. The 0.290 Mev
gamma and 0.963 Mev beta make up about 99 percent of the decay scheme.
3. The half-life is 2.69 days and 94 percent of the radiation dose is delivered
within the first eleven days.
4. The maximum range of the 0.963 Mev beta radiation is 3.8 mm in tissue.
5. The colloidal gold particles are basically inert.
The principle of depositing a high energy source in the form of colloidal particles
in the same locus as the tumor cells, namely, the regional lymph nodes is quite different
from extemal radiation in which the effectiveness is proportionately diminished by
linear distance.
Radioactive gold as a trillion point source of beta radiation has had increasing
clinical use for the treatment of malignancy. One of the most encouraging developments
has been in the treatment of women with cancer of the cervix. The results of this type
of therapy reported by Allen' have been encouraging. Radioactive gold is used in
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conjunction with radium and often surgery. The function of the radioactive gold is
to destroy the metastatic tumor in the broad ligaments and regional lymph nodes.
METHODS
Radioactive gold is injected into the broad ligament region in volumes of 35 cc on
each side aimed at three sites — obturator, hypogastric and paracervical. The amount
of radiation employed has been 50 mc in each parametria. Care is taken in the
handling of the material. Spillage and contact with the skin is avoided. Within 72
hours the patient is discharged from the hospital.
DISTRIBUTION
In suitable patients Wertheim hysterectomy and pelvic node dissection is usually
carried out 6 to 8 weeks after the injection of the radioactive gold. The radioactive
gold has been employed at the Henry Ford Hospital for the past 18 months. During
that period of time 15 cases have received radioactive gold. Nodes removed at time
of operation universally were black in color indicating the presence of radioactive gold.
Micropathological examination revealed aggregates of gold to be present in the nodes
with the greatest concentration to be seen in the periphery of the node. Calculation
of the amount of radiation in terms of reps delivered to the nodes per gram of tissue

Figure 1
Scintogram of typical distribution of radiation over the left broad ligament.
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has been determined by AUen^ The doses usually exceeded what is considered to be
cancericidal. Scintograms were performed on 7 patients. Figure I shows a very typical
distribution of radiation over the left broad ligament area in one patient. A l l tracings
showed the gold to be evenly distributed in the broad hgament regions. Investigators
in this field concur that the colloidal particles are picked up by the macrophages and
deposited in the regional lymph nodes. Our experimental work with rabbits reveals
that homogeneous interstitial injection of colloidal gold results in the' homogeneous
distribution of particles in the regional lymph nodes*.
Approximately 50 percent of the radioactive gold is removed at operation indicating
the remainder migrates beyond the bounds of the operation. This migration to succeeding nodes is substantiated in the work on rabbits since time-concentration curves of a
particular node show a very definite peak. This is, of course, desirable. Less than 1
percent enters the blood stream.
RESULTS
The potentiality of treating the regional lymphatics with radioactive colloidal gold
in carcinoma of the cervix was first investigated by Sherman, Nolan, and AUen^ The
recent report of Allen' using colloidal gold in the treatment of carcinoma of the cervix
bears mention. The work has now been in progress for six and one-half years. The
survival rates obtained in the gold series are shown in Table I , I I , I I I . Radiogold has
been employed in the treatment of cervical malignancy at Henry Ford Hospital for
the past 18 months. Fifteen cases have received parametrial gold. The cases according
to stage disease (League of Nations) are shown in Table IV.

STAGE I
Au'98 )
Radium )

X-ray and Radium
Alive without
Disease

No.

Wertheim

Alive without
Disease

No.
Treated

Treated

Total

+
—

35

No.

Percent

26

74.2

87

No.

Percent

79

90,8

Table I
Survival rates obtained in a series of Stage I cancer of the cervix patients treated with radioactive gold,
radium and Wertheim hysterectomy compared with patients treated with conventional x-ray therapy
and radium are shown above. In a small percentage of cases additional radium was given in lieu of
Werthdeim hysterectomy.
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STAGE I I
Au"8
„ ,.
Radium

X-ray and Radium

Alive without
Disease

No.

-1-

Wertheim

Alive without
Disease

No.

Treated

Total

(
•
1

Treated

69

No.

Percent

38

55.1

62

No.

Percent

55

88.7

Table I I
Survival rates obtained in a series of Stage I I cancer of the cervix patients treated with radioactive gold,
radium and Wertheim hysterectomy compared with patients treated with conventional x-ray therapy
and radium are shown above. In a small percentage of cases additional radium was given in lieu of
Wertheim hysterectomy.
STAGE I I I
Au"8
„ ,,
Radium

X-ray and Radium

Alive without
Disease

No.

-)—

Wertheim

Alive without
Disease

No.

Treated

Total

)
:•
]

Treated

48

No.

Percent

13

27.1

27

No.

Percent

16

59.2

Table I I I
Survival rates obtained in a series of Stage I I I cancer of the cervix patients treated with radioactive
gold and radium compared with patients treated with conventional x-ray therapy and radium are
shown above. In a small percentage of cases Wertheim hysterectomy was also performed in the
radioactive gold series.

Stage

No. Cases

I

6

II

6

III

3

IV

0
Table I V

Fifteen Cases Treated by Parametrial Radioactive Gold, according to Stage of Cancer. (League of
Nations). Nine operated. One death.
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Fourteen of the 15 cases are alive without disease. One patient, a League of
Nations Stage I I , developed distant metastases in the lungs and liver. A t the time of
her demise the pelvis was free of palpable tumor, and both ureters were unobstructed.
It seems Hkely that distant metastases were present at the time of the initial therapy.
Our figures suggest that we can perhaps approach the results obtained by Allen and
Sherman.
One of the most significant features of the series has been the absence of recognizable tumor in the lymph nodes removed at operation. Of the 15 cases, 9 were
operated. Of the 9 cases, 4 were classified as Stage I , 3 as Stage I I , and 2 as Stage I I I .
Meigs'' found positive nodes in 18 percent of the Stage I cases, and 45 percent positive
nodes in the Stage I I cases ( 4 ) . No figures on Stage I I I cases were presented. Of the
9 cases operated, only one, a Stage I I I case, demonstrated recognizable tumor cells in
a lymph node, and this was considered to be radiated tumor. Approximately 15 months
after treatment this patient is alive without evidence of disease.
COMPLICATIONS
The most frequent complication produced by gold therapy is leg pain. This pain
occurs from two to four weeks following therapy. Of the 15 cases treated with radiogold,
6 developed leg pain. The pain lasted from three to six months, but has cleared in all
cases. The distribution of leg pain suggests sacral nerve root involvement. One patient
developed a transient saddle block type of anesthesia.
Liver function studies were performed on three patients. No significant change
from normal was observed. No ureteral, bladder, or bowl fistulas developed. No
anemias or leukopenias secondary to radioactive gold were noted.
SUMMARY A N D CONCLUSIONS
Homogeneous distribution of colloidal gold in the regional lymph nodes is accomplished by homogeneous interstitial injection of the colloidal suspension. The deposition
of a trillion point source at the site of tumor metastasis results in tumor destruction in
this area. In the case of large collections of tumor cells, radioactive gold does not
effect the inner portion of that mass. The removal of such a mass must be performed
by surgery. Fortunately, in the case of cancer of the cervix, nodes found to be
completely replaced by tumor occurs as a very late development in the course of the
disease, but the infinite number of lymphatic pathways and regional lymph nodes
which have been sprinkled with cells can be eradicated by radioactive colloidal gold.
The encouraging survival figures which are being obtained by the use of radioactive gold in the treatment of cancer of the cervix attest to this fact. Fourteen of the
15 cases of cancer of the cervix treated in the past 18 months at Henry Ford Hospital
with radioactive gold, radium, and surgery are alive without evidence of disease. Nine
cases were operated. One showed recognizable tumor in lymph nodes removed at
operation. The chief complication was leg pain.
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